The company's financial position is characterized by a significant erosion of resources, with total assets declining from $28.8 million in 2024Q2 to $14.4 million in 2026Q1.
| Total Current Assets | 14.16M | 10.88M | 16.07M | 22.51M | 33.53M | 16.58M | 10.68M | 14.12M | 3.81M | 19.01M | 24.75M | 3.64M | 330K |
| Cash & Short-Term Investments | 13.73M | 10.28M | 16.02M | 22.43M | 33.36M | 16.39M | 10.09M | 13.91M | 2.85M | 18.47M | 24.03M | 3.62M | 317K |
| Cash Only | 13.73M | 10.28M | 16.02M | 22.43M | 33.36M | 16.39M | 10.09M | 13.91M | 2.85M | 18.47M | 24.03M | 3.62M | 317K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 2K | 32K | 0 | 0 | 0 | 0 | 48K | 57K | 34K | 46K | 0 | 0 | 0 |
| Total Non-Current Assets | 226K | 58.25M | 188K | 269K | 2K | 215K | 285K | 350K | 12K | 8K | 8K | 847K | 18K |
| Property, Plant & Equipment | 205K | 227K | 167K | 248K | 2K | 215K | 285K | 350K | 12K | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 21K | 21K | 21K | 21K | 0 | 0 | 0 | 0 | 0 | 8K | 8K | 837K | 0 |
| Total Assets | 14.39M | 69.12M | 16.26M | 22.78M | 33.53M | 16.8M | 10.97M | 14.47M | 3.82M | 19.02M | 24.75M | 4.49M | 348K |
| Asset Turnover | 0.00x | - | - | - | - | - | - | - | - | - | - | - | - |
| Asset Growth % | 274.63% | 325.11% | -28.62% | -32.07% | 99.62% | 53.16% | -24.19% | 278.74% | -79.91% | -23.18% | 451.31% | 1190.23% | - |
| Total Current Liabilities | 5.19M | 5.65M | 8.27M | 5.96M | 11.78M | 2.16M | 3.69M | 2.08M | 219K | 6.39M | 4.12M | 8.92M | 879K |
| Accounts Payable | 1.01M | 1.06M | 3.88M | 821K | 708K | 830K | 2.58M | 638K | 170K | 4.03M | 2.01M | 531K | 21K |
| Days Payables Outstanding | 45.87K | 20.36K | 58.99K | 42.81K | 9.23K | 4.21K | 14.03K | - | - | - | - | - | - |
| Short-Term Debt | 71K | 68K | 0 | 0 | 0 | 0 | 0 | 0 | 9.44M | 1.35M | 0 | 6.42M | 737K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 3.73M | 3.69M | 1.13M | 942K | 10.8M | 0 | 40K | 189K | -9.42M | 306K | 706K | 347K | 91K |
| Current Ratio | 2.73x | 1.93x | 1.94x | 3.78x | 2.85x | 7.69x | 2.89x | 6.78x | 17.39x | 2.97x | 6.00x | 0.41x | 0.38x |
| Quick Ratio | 2.73x | 1.93x | 1.94x | 3.78x | 2.85x | 7.69x | 2.89x | 6.78x | 17.39x | 2.97x | 6.00x | 0.41x | 0.38x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 123K | 58.14M | 58K | 136K | 0 | 45K | 70K | 94K | 16.89M | 8.69M | 1K | 7.95M | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 118K | 8.68M | 0 | 0 | 0 |
| Capital Lease Obligations | 280K | 142K | 58K | 136K | 0 | 45K | 70K | 94K | 23K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 58M | 58M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16.75M | 3K | 1K | 7.95M | 0 |
| Total Liabilities | 5.32M | 63.79M | 8.33M | 6.1M | 11.78M | 2.2M | 3.77M | 2.18M | 17.11M | 15.08M | 4.12M | 16.87M | 879K |
| Total Debt | 194K | 210K | 136K | 203K | 0 | 71K | 94K | 116K | 9.58M | 10.04M | 0 | 6.42M | 737K |
| Net Debt | -13.54M | -10.07M | -15.88M | -22.23M | -33.36M | -16.32M | -9.99M | -13.79M | 6.73M | -8.44M | -24.03M | 2.8M | 420K |
| Debt / Equity | 0.02x | 0.04x | 0.02x | 0.01x | - | 0.00x | 0.01x | 0.01x | - | 2.55x | - | - | - |
| Debt / EBITDA | -0.01x | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.98x | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -5.37x | - | - | -917.09x | -387.15x | -115.82x | - | -9.41x | -4.84x |
| Total Equity | 9.07M | 5.33M | 7.93M | 16.68M | 21.75M | 14.6M | 7.2M | 12.29M | -13.29M | 3.94M | 20.63M | -12.38M | -531K |
| Equity Growth % | -25.93% | -32.76% | -52.47% | -23.29% | 49% | 102.65% | -41.4% | 192.52% | -437.12% | -80.9% | 266.66% | -2231.45% | - |
| Book Value per Share | 1.87 | 3.02 | 11.25 | 36.19 | 743.69 | 1664.99 | 1172.55 | 6211.22 | -63569.38 | 25101.91 | 147371.43 | -89064.75 | -3820.14 |
| Total Shareholders' Equity | 9.07M | 5.33M | 7.93M | 16.68M | 21.75M | 14.6M | 7.2M | 12.29M | -13.29M | 3.94M | 20.63M | -12.38M | -531K |
| Common Stock | 5K | 2K | 9K | 5K | 25K | 1K | 20K | 16K | 0 | 18K | 17K | 12K | 9K |
| Retained Earnings | -152.65M | -148.83M | -135.86M | -108.27M | -95.8M | -81.83M | -66.54M | -36.87M | -15.55M | -60.47M | -27.06M | -12.39M | -584K |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 4K | 14K | 12K | 2K | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liquidity and clinical execution
As reported in recent financial filings, MetaVia's total assets have contracted from $28.8 million in 2024Q2 to $14.4 million by 2026Q1, reflecting a consistent depletion of resources as the company funds its clinical-stage R&D programs without the benefit of recurring commercial revenue streams.
The downward trend in total assets suggests that the company is consuming its capital base at a rate that outpaces its ability to replenish it through non-dilutive means. This trajectory implies that the firm's operational runway is narrowing, forcing a reliance on external financing to maintain its current research pipeline.
Based on the company's latest quarterly data, cash reserves have declined to $13.7 million in 2026Q1 from a peak of $27.9 million in 2024Q2, indicating that the firm's liquidity buffer is under significant strain as it navigates the high-cost environment of Phase 2 clinical trials.
While the current ratio of 2.73 appears superficially healthy, it is heavily skewed by the limited nature of current liabilities rather than an abundance of liquid assets. Investors should monitor the cash burn rate closely, as the current trajectory suggests that the company may face a liquidity crunch within the next several quarters.
According to historical balance sheet data, MetaVia's retained earnings have plummeted to a deficit of $152.7 million as of 2026Q1, a clear indicator of the persistent, long-term losses inherent in the company's current clinical-stage business model and its reliance on equity-based financing.
The erosion of equity highlights the cumulative impact of R&D spending and administrative overhead on the company's financial position. This trend suggests that shareholder value is being consistently diluted to support ongoing operations, which warrants further investigation into the company's long-term path toward sustainable capital generation.
As indicated by the provided financial statements, the company's asset base is almost entirely devoid of tangible value, with net PPE totaling only $205,000 in 2026Q1, which underscores the extreme reliance on intangible clinical trial progress to justify the firm's current valuation.
The lack of significant physical assets implies that the company's value is entirely contingent upon the success of its GPR119-targeted therapeutic pipeline. This structure makes the balance sheet highly sensitive to clinical trial outcomes, as there is little underlying asset value to provide a floor in the event of negative data.
Quick answers to the most common questions about buying MTVA stock.
As of 2025, MetaVia Inc. (MTVA) had total assets of $69.1M including $10.9M in current assets.
MetaVia Inc. (MTVA) carries total debt of $0.2M, offset by $10.3M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
MetaVia Inc. (MTVA) has total shareholders' equity (book value) of $5.3M ($3.02 book value per share). Book value represents the net worth of the company belonging to common stock holders.
MetaVia Inc. (MTVA) reported a current ratio of 1.93x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.